Total Payments
$34,254
2024 Payments
$13,991
Companies
70
Transactions
342
Medicare Patients
21,800
Medicare Billing
$7.7M
Payment Breakdown by Category
Consulting$15,424 (45.0%)
Other$8,929 (26.1%)
Food & Beverage$7,111 (20.8%)
Travel$2,116 (6.2%)
Education$482.96 (1.4%)
Research$190.25 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $15,424 | 12 | 45.0% |
| Food and Beverage | $7,111 | 308 | 20.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,980 | 2 | 20.4% |
| Travel and Lodging | $2,116 | 3 | 6.2% |
| Honoraria | $1,750 | 1 | 5.1% |
| Education | $482.96 | 13 | 1.4% |
| Long term medical supply or device loan | $199.40 | 2 | 0.6% |
| Unspecified | $190.25 | 1 | 0.6% |
Payments by Type
General
$34,064
341 transactions
Research
$190.25
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| JAZZ PHARMACEUTICALS INC. | $8,455 | 9 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $6,624 | 15 | $0 (2024) |
| CATALYST PHARMACEUTICALS, INC. | $3,270 | 3 | $0 (2021) |
| Seattle Genetics, Inc. | $2,180 | 8 | $0 (2018) |
| BeiGene USA, Inc. | $2,036 | 4 | $0 (2024) |
| GlaxoSmithKline, LLC. | $1,753 | 7 | $0 (2024) |
| Seagen Inc. | $1,486 | 7 | $0 (2023) |
| Genentech USA, Inc. | $1,372 | 12 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $612.26 | 26 | $0 (2024) |
| TerSera Therapeutics LLC | $439.09 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $13,991 | 95 | JAZZ PHARMACEUTICALS INC. ($8,441) |
| 2023 | $2,017 | 69 | TerSera Therapeutics LLC ($419.00) |
| 2022 | $4,202 | 73 | AstraZeneca Pharmaceuticals LP ($1,402) |
| 2021 | $7,480 | 58 | CATALYST PHARMACEUTICALS, INC. ($1,750) |
| 2020 | $3,308 | 11 | AstraZeneca Pharmaceuticals LP ($1,665) |
| 2019 | $690.46 | 20 | Dova Pharmaceuticals ($97.69) |
| 2018 | $1,444 | 10 | Seattle Genetics, Inc. ($1,142) |
| 2017 | $1,122 | 6 | Seattle Genetics, Inc. ($1,038) |
All Payment Transactions
342 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $26.62 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $23.39 | General |
| 12/11/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.37 | General |
| 12/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 12/10/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $28.52 | General |
| Category: Oncology | ||||||
| 12/06/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Geron Corporation | RYTELO (Drug) | Food and Beverage | In-kind items and services | $26.42 | General |
| Category: MYELODYSPLASTIC SYNDROME | ||||||
| 12/03/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $18.25 | General |
| Category: Oncology | ||||||
| 11/26/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $19.42 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $17.30 | General |
| Category: Hematology | ||||||
| 11/19/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $21.96 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 11/12/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $23.02 | General |
| Category: Iron Deficiency Anemia | ||||||
| 11/06/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $1,675.00 | General |
| Category: Oncology | ||||||
| 11/05/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $16.60 | General |
| Category: ONCOLOGY | ||||||
| 11/02/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Food and Beverage | In-kind items and services | $69.14 | General |
| Category: HEMATOLOGY | ||||||
| 10/30/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Food and Beverage | In-kind items and services | $30.45 | General |
| Category: Oncology | ||||||
| 10/29/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $28.49 | General |
| Category: ONCOLOGY | ||||||
| 10/22/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $17.20 | General |
| Category: Oncology | ||||||
| 10/16/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $18.50 | General |
| Category: Oncology | ||||||
| 10/02/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $25.67 | General |
| Category: Oncology | ||||||
| 10/01/2024 | Genentech USA, Inc. | Columvi (Biological), Lunsumio, Polivy | Food and Beverage | In-kind items and services | $23.49 | General |
| Category: BioOncology | ||||||
| 09/25/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ALUNBRIG (Drug) | Food and Beverage | In-kind items and services | $21.53 | General |
| Category: ONCOLOGY | ||||||
| 09/24/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | In-kind items and services | $17.14 | General |
| Category: Oncology | ||||||
| 09/17/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $12.38 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED PHASE 2 TRIAL OF AM0010 IN COMBINATION WITH PEMBROLIZUMAB VS. PEMBROLIZUMAB ALONE AS FIRST-LINE THERAPY IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE HIGH PD-L1 EXPRESSION | Eli Lilly and Company | $190.25 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 57 | 5,122 | 142,177 | $4.0M | $1.8M |
| 2022 | 57 | 5,601 | 225,401 | $4.4M | $2.0M |
| 2021 | 56 | 5,314 | 233,250 | $4.4M | $1.9M |
| 2020 | 59 | 5,763 | 237,185 | $4.4M | $2.0M |
Total Patients
21,800
Total Services
838,013
Medicare Billing
$7.7M
Procedure Codes
229
All Medicare Procedures & Services
229 procedure records from CMS Medicare Utilization — Page 1 of 10
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 13 | 19,203 | $1.2M | $829,294 | 69.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 69 | 13,081 | $385,202 | $227,002 | 58.9% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 97 | 12,000 | $354,840 | $198,956 | 56.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 234 | 701 | $242,847 | $92,365 | 38.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 397 | 768 | $198,298 | $68,625 | 34.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 82 | 586 | $109,700 | $57,360 | 52.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 444 | 613 | $107,060 | $35,383 | 33.0% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 28 | 219 | $118,705 | $28,620 | 24.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 193 | 538 | $88,709 | $25,598 | 28.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 755 | 2,926 | $77,371 | $22,135 | 28.6% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 153 | 987 | $91,050 | $21,648 | 23.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 720 | 1,908 | $15,264 | $14,959 | 98.0% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 16 | 80 | $85,207 | $14,361 | 16.9% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 12 | 2,320 | $62,014 | $14,330 | 23.1% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 282 | 1,089 | $21,780 | $11,220 | 51.5% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 27 | 28,050 | $70,686 | $10,866 | 15.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 69 | 80 | $39,506 | $10,721 | 27.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 66 | 66 | $35,769 | $9,974 | 27.9% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 38 | 184 | $66,100 | $8,943 | 13.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 146 | 800 | $41,680 | $8,338 | 20.0% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 60 | 329 | $44,073 | $7,800 | 17.7% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 13 | 139 | $19,614 | $7,413 | 37.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 48 | 117 | $20,534 | $7,120 | 34.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 57 | 57 | $23,955 | $6,843 | 28.6% |
| 96361 | Infusion into a vein for hydration, each additional hour | Office | 2023 | 68 | 527 | $25,407 | $5,077 | 20.0% |
About Dr. Nagesh Jayaram, MD
Dr. Nagesh Jayaram, MD is a Internal Medicine healthcare provider based in Jacksonville, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/10/2008. The National Provider Identifier (NPI) number assigned to this provider is 1740466564.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nagesh Jayaram, MD has received a total of $34,254 in payments from pharmaceutical and medical device companies, with $13,991 received in 2024. These payments were reported across 342 transactions from 70 companies. The most common payment nature is "Consulting Fee" ($15,424).
As a Medicare-enrolled provider, Jayaram has provided services to 21,800 Medicare beneficiaries, totaling 838,013 services with total Medicare billing of $7.7M. Data is available for 4 years (2020–2023), covering 229 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location Jacksonville, NC
- Active Since 01/10/2008
- Last Updated 03/31/2021
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1740466564
Products in Payments
- ZEPZELCA (Drug) $8,455
- FIRDAPSE (Drug) $3,270
- IMFINZI (Biological) $3,053
- BRUKINSA (Drug) $2,036
- CALQUENCE (Drug) $1,718
- ZEJULA (Drug) $1,707
- TAGRISSO (Drug) $1,665
- ADCETRIS (Biological) $1,471
- Zoladex (Drug) $439.09
- KEYTRUDA (Biological) $413.58
- OPDIVO (Biological) $290.56
- KISQALI (Drug) $283.33
- REBLOZYL (Biological) $223.76
- JEVTANA (Drug) $171.90
- Lenvima (Drug) $161.24
- SARCLISA (Biological) $156.27
- Doptelet (Drug) $114.03
- IMBRUVICA (Drug) $113.38
- FOTIVDA (Drug) $108.32
- Enhertu (Drug) $104.03
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Jacksonville
Siddharth Wayangankar, Md, MD
Internal Medicine — Payments: $1.3M
Internal Medicine $1.3M
Dr. Alan Miller, M.d, M.D
Internal Medicine — Payments: $770,575
Internal Medicine $770,575
Kalina Sanders, M.d, M.D
Internal Medicine — Payments: $626,907
Internal Medicine $626,907
Jose Soto Soto, Md, MD
Internal Medicine — Payments: $576,809
Internal Medicine $576,809
Dr. Jennifer Fulton, Md, MD
Internal Medicine — Payments: $556,016
Internal Medicine $556,016
Dr. Francis Farraye, M.d, M.D
Internal Medicine — Payments: $504,399
Internal Medicine $504,399